Efficacy, Durability, and Safety of VYC-17. 5L Hyaluronic Acid Dermal Filler for Facial Enhancement

BACKGROUNDFacial aesthetics encompasses a variety of techniques to revitalize the face through aesthetic medicine. Satisfaction with one's face is important to well-being, leading people to seek to maintain their youthful appearance throughout their lives. Accordingly, many techniques have been developed for facial rejuvenation. VYC-17.5L (Volift/Vollure) is a hyaluronic acid–based dermal filler utilized for facial enhancement; however, evidence regarding its long-term efficacy and safety remains inconsistent.

METHODSFollowing PRISMA guidelines, a systematic search was performed across PubMed, Scopus, Web of Science, ScienceDirect, Embase via Ovid, and Cochrane Library to identify studies evaluating VYC-17.5L (Volift/Vollure) hyaluronic acid dermal fillers for facial aesthetic enhancement. Eligible studies included randomized controlled trials, prospective cohort studies, retrospective observational studies, and case series with ≥ 10 patients. Risk of bias was assessed using the Cochrane RoB 2 tool for randomized studies and ROBINS-I for non-randomized studies. Single-arm meta-analysis was performed to evaluate aesthetic outcomes (GAIS, FACE-Q, NLFSS, WSRS, and responder rates) and safety outcomes.

RESULTSEleven studies comprising 967 participants were included. Clinician-assessed GAIS demonstrated a time-dependent decline, reaching its peak at 3 months (87%–90%) and decreasing to (24%–33%) at 12 months. Patient-reported GAIS responder rates remained high through 6 months (85%–95%) but declined to 62% at 9 months and 53% at 12 months. FACE-Q responder rates remained high across the available 12-month follow-up. NLFSS responder rates remained consistently high (≥ 89%) up to 6 months, indicating sustained improvement in nasolabial fold severity. Adverse events were predominantly mild and transient; clinician-reported frequencies were low, whereas patient-reported frequencies were considerably higher.

CONCLUSIONVYC-17.5L demonstrates favorable short-term efficacy and safety for facial rejuvenation, with high patient satisfaction. Objective aesthetic improvements decline over time, highlighting the time-limited nature of treatment effects and the importance of appropriate patient counseling. Trial Registration: PROSPERO number: CRD420261279046

Abstract from Crossref